NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
Yes. The Royal College of Pathologists and the British Society of Haematologists highlighted that "if CTCL with <5% CD30 expression was excluded this may deny a small number of patients a possibly efficacious drug as a study found 1 of 6 may respond with CD30<5%".	

2.	What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
The remit and population specified in the scope are broad and do not specify a percentage of CD30 expression. This is consistent with the inclusion criteria for the clinical trials of brentuximab vedotin. If the final marketing authorisation is restricted by percentage of CD30 expressed, NICE will only appraise brentuximab vedotin for the group(s) specified in the marketing authorisation.	

3.	Has any change to the draft scope been agreed to highlight potential equality issues?
None	

4.	Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
None	

Approved by Associate Director (name): ……Frances Sutcliffe……
Date: 12/10/2017